Related Experiment Video

Updated: Apr 6, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough

Fei Zhou1, Cai-Cun Zhou2

  • 1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, P. R. China. drzhoufei@126.com.

Chinese Journal of Cancer
|July 19, 2015
PubMed

Insights

Non-small cell lung cancer (NSCLC) treatment is shifting from chemotherapy to targeted therapies based on molecular alterations. This review explores alternative targeted treatments beyond epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for advanced NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) classification has evolved from histology to molecular alterations.
  • Identifying specific oncogenic drivers has revolutionized advanced NSCLC treatment paradigms.
  • Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) exemplify precision medicine in NSCLC.

Purpose of the Study:

  • To provide an overview of alternative targeted therapies for advanced NSCLC.
  • To discuss EGFR-TKIs for wild-type EGFR NSCLC.
  • To review other targeted agents in clinical development for NSCLC.

Main Methods:

  • Literature review of targeted therapy in NSCLC.
  • Analysis of current clinical applications and developmental stages of targeted agents.
  • Focus on treatments beyond standard EGFR mutation-targeted therapies.

Main Results:

  • The shift towards targeted therapy based on molecular drivers is a key trend in advanced NSCLC.
  • EGFR-TKIs are established for EGFR-mutated NSCLC, but alternatives are emerging.
  • Various targeted agents are in development for different NSCLC molecular subtypes.

Conclusions:

  • Precision medicine is transforming NSCLC treatment, moving beyond histology.
  • Alternative targeted therapies offer new hope for patients with advanced NSCLC, including those with wild-type EGFR.
  • Continued research and development of targeted agents are crucial for improving NSCLC outcomes.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K